Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to $601.6 million.

  • Nuvation Bio's Liabilities and Shareholders Equity rose 524.55% to $601.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year decrease of 495.98%. This contributed to the annual value of $540.6 million for FY2024, which is 1301.05% down from last year.
  • Per Nuvation Bio's latest filing, its Liabilities and Shareholders Equity stood at $601.6 million for Q3 2025, which was up 524.55% from $647.2 million recorded in Q2 2025.
  • Over the past 5 years, Nuvation Bio's Liabilities and Shareholders Equity peaked at $657.1 million during Q1 2023, and registered a low of $492.5 million during Q1 2025.
  • In the last 3 years, Nuvation Bio's Liabilities and Shareholders Equity had a median value of $613.1 million in 2024 and averaged $601.1 million.
  • Over the last 5 years, Nuvation Bio's Liabilities and Shareholders Equity had its largest YoY gain of 881.46% in 2025, and its largest YoY loss of 1967.56% in 2025.
  • Quarter analysis of 3 years shows Nuvation Bio's Liabilities and Shareholders Equity stood at $621.5 million in 2023, then dropped by 13.01% to $540.6 million in 2024, then grew by 11.27% to $601.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $601.6 million for Q3 2025, versus $647.2 million for Q2 2025 and $492.5 million for Q1 2025.